- PHARMACEUTICAL ANTIRETROVIRAL COMPOSITION
-
The present invention relates to a pharmaceutical antiretroviral composition comprising (i) a nucleoside reverse-transcriptase inhibitor selected from lamivudine and emtricitabine, (ii) extended release nevirapine, and (iii) tenofovir; a process for preparing such composition and the use of such composition in medicine, particularly for the prophylaxis and/or treatment of diseases caused by retroviruses.
- -
-
Page/Page column
(2014/07/22)
-
- MIXTURE OF FUCOSYLATE LACTOSES
-
A method to form a mixture containing at least one of 2'-FL (2'-O-fucosyllactose, Fuc(a1-2)Gai(β1-4)Glc) and 3-FL (3-O-fucosyllactose, Gal(β1-4)[Fuc(a1-3)]Glc)characterized in that DFL (difucosyl-lactose, Fuc(a1-2)Gal(β1-4)[Fuc(a1-3)]Glc) is subjected to partial hydrolysis, e.g. enzymatic hydrolysis or acid hydrolysis,
- -
-
Page/Page column 10; 11
(2014/07/07)
-
- Pharmaceutical composition for the prevention and treatment of liver disease comprising a lonicera caerulea L. Var. Edulis extract
-
Disclosed herein is a pharmaceutical composition having preventative and therapeutic effects on liver diseases, comprising an extract from Lonicera caerulea L. var. edulis. The composition has preventative and therapeutic effects on hepatitis, liver cirrhosis, fatty liver, and the like.
- -
-
-
- Popping oral pharmaceutical compositions
-
Disclosed are popping pharmaceutical compositions, which comprise OTC or prescription drug, and popping material. The popping material includes pressurized gas trapped within cavities of a pharmaceutically acceptable material in a manner that allows the gas to escape from the pharmaceutical composition upon dissolution, contact with saliva or shattering of the popping material. Such an oral pharmaceutical composition may be popular with children that will prefer it on other ones, which do not pop. Methods for preparation of such oral pharmaceutical compositions are also disclosed.
- -
-
-
- Synthesis and characterization of bis(glycosylamino)benzenes based on reducing disaccharides
-
Synthesis of bis(glycosylamino)benzenes, derived from disaccharides lactose, maltose, and cellobiose, by direct condensation and their characterization are described.
- Metlitskikh,Koroteev,Nifantyev
-
p. 1272 - 1275
(2007/10/03)
-
- Modified carrier particles for use in dry powder inhalers
-
The invention relates to carrier particles for use in pharmaceutical compositions for the pulmonary administration of medicaments by means of dry powder inhalers. In particular, the invention relates to a novel technological process for obtaining a carrier modified so as to improve the efficiency of redispersion of active particles and hence increase the respirable fraction. After the treatment of the invention, the surface of said modified carrier particles can also be coated with a suitable additive so as to further improve the respirable fraction.
- -
-
-
- DRUGS
-
The present invention relates to a medicine which comprises a compound (I) of the formula:[wherein the ring M is a heterocylic ring having -N=Ca and Rb are bound to each other to form the ring A, or they are the same or different each representing a hydrogen atom or a substituent on the ring M;the rings A and B each is an optionally substituted homocycle or heterocycle, and at least one of them is an optionally substituted heterocycle;the ring C is an optionally substituted homocycle or heterocycle;the ring Z is an optionally substituted nitrogen-containing heterocycle; andn is an integer of 1 to 6] or a salt thereof in combination with a drug having an emetic action. The compounds (I) or their salts are useful as anti-emetic drugs. Particularly, vomiting caused by drugs having an emetic action can be inhibited by these compounds rapidly and safely at a low dose.
- -
-
-
- Preventives and remedies for medicinal and alcoholic poisoning
-
Preventives or remedies for medicinal and alcoholic poisoning contain as a pharmaceutically effective component phytic acid or its salt which may be an innoxious metal salt, or an innoxious salt with an organic base, a basic amino acid or an organic ester residue.
- -
-
-
- Anti-hypertensive substituted 2-azabicyclooctane-3-carboxylic acids
-
Compounds of formula (I): STR1 in which E denotes a lower alkyl group, or preferably a hydrogen atom, and their addition salts with a pharmaceutically acceptable acid or base, the preparation thereof and pharmaceutical compositions containing them.
- -
-
-
- Granular delayed-release form of pharmaceutically active substances
-
A granular delayed-release form of pharmaceutically active substances, which is prepared by coating a granulated or crystalline pharmaceutically active substance, or mixtures thereof, with a coating material mixture consisting essentially of a homogeneous mixture of a poly(H+meth)-acrylic acid-(methyl+ethyl)ester which is insoluble but dispersible in water and an ethyl cellulose which is insoluble but dispersible in water in the weight ratio of 20:1 to 1:5, is presented, which is characterized by the fact that the coated granules are heated for at least 5 minutes at elevated temperatures ranging from between 50° to 120° C.
- -
-
-
- Galenical formulation of toloxatone
-
A new formulation for the oral administration of Toloxatone, an anti-depressant, contains 400 to 600 mg of Toloxatone per unit dose. Such a high Toloxatone content is possible due to the discovery that Toloxatone is competitive with Tyramine towards the A form of a monomine oxidase, and thus does not cause hypertensive crisis. The anti-depressant composition of this invention can therefore be administered to the patient even when Tyramine is present in the patient's system.
- -
-
-
